Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

Long-acting somatostatin

Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).

OTHER

Saline solution

Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).

Trial Locations (5)

24128

"Hospital Ospedali Riuniti Unit of Nephrology and Dialysis", Bergamo

Unknown

"University Federico II of Naples", Napoli

Hospital Cà Foncello, Treviso

"Hospital V. Fazzi - Unit of neprology and Dialysis", Lecce

"Hospital Presidio Osp. Maggiore Policlinico", Milan

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00309283 - Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study | Biotech Hunter | Biotech Hunter